NASDAQ:EMMA - Emmaus Life Sciences Stock Price, News & Analysis

$3.37
+0.01 (+0.30 %)
(As of 08/21/2019 04:00 PM ET)
Today's Range
$3.29
Now: $3.37
$3.40
50-Day Range N/A
52-Week Range
$2.81
Now: $3.37
$14.94
Volume26,286 shs
Average Volume38,961 shs
Market Capitalization$159.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EMMA
CUSIPN/A
CIKN/A
Phone310-214-0065

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.32 million
Book Value$2.60 per share

Profitability

Net Income$-9,590,000.00
Net Margins-489.28%

Miscellaneous

Employees28
Market Cap$159.96 million
Next Earnings Date8/26/2019 (Estimated)
OptionableNot Optionable

Receive EMMA News and Ratings via Email

Sign-up to receive the latest news and ratings for EMMA and its competitors with MarketBeat's FREE daily newsletter.


Emmaus Life Sciences (NASDAQ:EMMA) Frequently Asked Questions

What is Emmaus Life Sciences' stock symbol?

Emmaus Life Sciences trades on the NASDAQ under the ticker symbol "EMMA."

When is Emmaus Life Sciences' next earnings date?

Emmaus Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, August 26th 2019. View Earnings Estimates for Emmaus Life Sciences.

Has Emmaus Life Sciences been receiving favorable news coverage?

News articles about EMMA stock have trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Emmaus Life Sciences earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Emmaus Life Sciences.

Who are some of Emmaus Life Sciences' key competitors?

What other stocks do shareholders of Emmaus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emmaus Life Sciences investors own include Ecobalt Solutions (ECS), XBiotech (XBIT), Spherix (SPEX), Guardant Health (GH) and FuelCell Energy (FCEL).

Who are Emmaus Life Sciences' key executives?

Emmaus Life Sciences' management team includes the folowing people:
  • Dr. Yutaka Niihara M.P.H., M.D., M.P.H, Chairman & CEO (Age 59)
  • Mr. Willis C. Lee, Vice Chairman & COO (Age 59)
  • Ms. Lan T. Tran M.P.H., M.P.H, Pres & Chief Admin. Officer (Age 43)
  • Mr. Yasushi Nagasaki CPA, Sr. VP of Fin. (Age 52)
  • Mr. Joseph C. Sherwood III, Chief Financial Officer

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emmaus Life Sciences' stock price today?

One share of EMMA stock can currently be purchased for approximately $3.37.

How big of a company is Emmaus Life Sciences?

Emmaus Life Sciences has a market capitalization of $159.96 million and generates $1.32 million in revenue each year. The company earns $-9,590,000.00 in net income (profit) each year or ($11.16) on an earnings per share basis. Emmaus Life Sciences employs 28 workers across the globe.View Additional Information About Emmaus Life Sciences.

What is Emmaus Life Sciences' official website?

The official website for Emmaus Life Sciences is http://www.myndanalytics.com/.

How can I contact Emmaus Life Sciences?

Emmaus Life Sciences' mailing address is 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503. The company can be reached via phone at 310-214-0065 or via email at [email protected]


MarketBeat Community Rating for Emmaus Life Sciences (NASDAQ EMMA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  14
MarketBeat's community ratings are surveys of what our community members think about Emmaus Life Sciences and other stocks. Vote "Outperform" if you believe EMMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EMMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel